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                                  INTRODUCTION
              Impairment of olfaction in Parkinson’s disease (PD) was first recognized in  the 
1970s1,2,  but it is mainly in the past decade that insights into its pathogenic  basis and 
specificity have occurred.  Various degrees of olfactory dysfunction occur  in some other 
Parkinsonian syndromes, but a marked reduction in the sense of smell  remains a highly 
characteristic feature of PD. The early or pre clinical detection of Parkinson’s disease is 
increasingly recognized as an area in which olfactory testing may be of value.Research 
findings  have  confirmed  a   role  for  olfactory  testing  in  the  differential  diagnosis 
movement  disorders, and  suggest that this approach is currently underused in clinical 
practice. Validated test  batteries are now available that may prove to be of practical use 
in the differential  diagnosis of Parkinsonian syndromes and indeterminate tremors.
                                                        
                                                              
                                                          
                       REVIEW   OF  LITERATURE
HISTORY
               
                Since the pioneering work of Valentin (1848), who determined the lowest 
concentration of an odorous gas that a subject could perceive, a plethora of  nominally 
distinct  olfactory  tests  has  been  developed,  including  tests  of  sensitivity(e.g.,  odor 
detection  and  recognition  thresholds),discrimination,  identification,   memory  and 
suprathreshold intensity (for reviews, see Cain, 1978;Doty, 1991, 1992;  Engen, 1982; 
Koster,  1975;  Takagi,1989;  Wenzel,  1948).  Katerina  Markopoulou  et  al,Doty  et 
al&Stern  et  al  have  extensively  studied  olfactory  functions  in  various  types  of 
parkinsonian patients and they have found out the usefulness of doing olfactory function 
tests in he diagnosis of various subtypes of parkinsonism.Doty et al have developed the 
olfactory  function  test  kit,the  University  of  Pennsylvania  Smell  Identification   Test 
(UPSIT) in 1988 and have researched in detail about the olfactory impairment in various 
neurodegenerative diseases like parkinsonism,various types of dementia and hereditary 
ataxias.
                    Anatomy of the  olfactory tract is illustrated in the next page.
                   
              OLFACTORY SYSTEM STRUCTURE AND     
                                   ORGANIZATION
                    
        The olfactory system is composed of the olfactory epithelium, the olfactory nerves, 
the olfactory bulbs,the olfactory tracts, and the median and lateral olfactory striae that 
terminate in the contralateral hemisphere or the ipsilateral amygdaloid nucleus, septal 
nuclei and hypothalamus. The olfactory epithelium is located on the superior- posterior 
aspect of the nasal septum and lateral walls of the nasal cavity and contains the olfactory 
sensory neurons (OSNs).  The OSNs are generated in situ from stem cells. Aging OSNs 
are replaced by cell division that persists into adulthood and throughout the adult life. 
The life span of an OSN is in the range of weeks to months. The OSNs are bipolar 
neurons, the axons of which form the olfactory nerves and pass through the cribiform 
plate and terminate in the olfactory bulb, where they synapse with second order neurons 
and interneurons.  In the olfactory bulb, the OSN axon terminates in a glomerulus differs 
in  different  mammalian  species.   The  axon  of  the  second-order  neurons  form  the 
olfactory tracts located in the orbit surfaces of the frontal lobes.  
  
As it courses centrally, the olfactory tract becomes divided   into the median and lateral 
olfactory striae.  In an organization analogous to that of the visual pathways, median 
stria  fibres  decussate  through the  anterior  commisure,  join  fibres  from the  opposite 
olfactory tract, and terminate in the contralateral hemisphere, while lateral striae fibers 
reach  the  primary  olfactory  cortex  (piriform cortex)  and  terminate  in  the  ipsilateral 
amygdaloid nucleus, septal nuclei, and hypothalamus.
      In humans, odor detection of airborne odorants appears to be very efficient, but odor 
discrimination is considerably less efficient.   Olfactory perception is initiated by the 
activation of odorant  receptors  by odorous ligands. Airborne odorants stimulate the 
olfactory sensory neurons (OSNs), contained in the olfactory epithelium.  It is thought 
that the functional heterogeneity of the OSNs is derived from  a very large number of 
odorant receptors(OR) that are expressed in the OSNs. In the last decade, approximately 
1000 odorant  receptors (OR) genes have been identified in humans.  These represent 
approximately 1%  of the human genome.  Interestingly, a large subset (almost two-
thirds) of these genes appears to be nonfunctional; ie., they are pseudogenes.  The OR 
genes are distributed in clusters on all chromosomes except chromosome 20 and the Y 
chromosome.  This clustering has been observed in many different species, including 
mice, rats, zebrafish and humans. There does not appear to be any particular pattern to 
be clustering of the OR genes,and they can often be intermixed with other gene families 
such as T-cell receptor and beta-globin genes.  The OR genes are intronless and have 
open reading frames (ORF)of approximately1kb.  Based on aminoacid similarity they 
have been categorized into families and subfamilies.  The predicted amino acid sequence 
indicates the presence of seven transmembrane domains, a characteristic of G- protein 
coupled  receptors.   Each  OSN  expresses  a  single  allele  of  a  single  OR  gene2 and 
therefore  the  olfactory  epithelium consists  of  distinct  OSN populations  (reviewed in 
References  82 through 84).
         How is the sensitivity of  OSN translated into the specificity of individual smell? 
The  principles  underlying  this  specificity  are  still  a  matter  of  debate,  but  some 
interesting patterns are emerging.  Both peripheral and central mechanisms seem to play 
an important role.   In the periphery, specificity appears to be generated both by the OSN 
expressing a single allele of a single OR gene and by the pattern of connections that the 
OSN forms.  All neurons expressing  a single OR gene project axons that synapse in one 
medial and one lateral glomerulus of the olfactory bulb, which represents the first relay 
station of the olfactory pathway.  It appears that the   OR plays a role of organizing the 
connectivity of the olfactory map3.  The glomerulus containing the second order neurons 
appear  to  serve  as  an  “odorant  feature”  via  mechanisms  involving  lateral  feedback 
inhibition and excitation and temporal synchrony.  Interestingly,  in rodents,  voltage 
sensitive dye imaging has revealed that there are differences in the response latency and 
the response time course across different glomeruli in the olfactory bulb.  The pattern of 
activity at the level of glomerulus evolves over time and depends also on the identity  of 
the different glomeruli.  Both the temporal and the spatial  context of the odor-evoked 
response is critical.  The temporal patterning may be imposed both by the odor carrier 
medium,   the  sampling  activity,  or  by  the  inherent  neural  dynamics  of  the  cells 
comprising the olfactory bulb4,5.  At the system level, it has been proposed that all odors 
are initially encoded as “objects” in the piriform cortex and that odor perception depends 
on higher cognitive functions such as memory and neural plasticity6.
            Odors have long been thought to be linked to emotional responses, yet an 
association at the anatomical level has only recently been clearly demonstrated.  Studies 
of  patients  with focal  brain injuries suggest  that  the caudal  orbitofrontal  and medial 
temporal  cortices  are  involved  in  odor  perception.   Using  event-related  fMRI7, 
researchers were able to show the responses could be identified in the piriform cortex in 
a rostrocaudal axis.  The amygdala was activated bilaterally by all odors, regardless of 
valence.  In the posterior orbitofrontal cortex, pleasant odors segregated in the lateral 
aspects.   fMRI  studies  have  shown  that  odors  can  activate  the  cerebellum  in  a 
concentration-dependent manner8.  These studies provide direct evidence in humans of 
the heterogeneity of brain regions involved in odor processing and that there is coupling 
between olfaction,  emotion,  and higher  cognitive processes.   At  the same time,  this 
heterogeneity of brain regions involved in normal nervous system function indicates its 
vulnerability in disease states and neurodegenerative processes.
           In summary, the analysis of the olfactory system at the molecular, cellular, and 
system  level  has  identified  a  rather  complicated  organization  that  implicates  both 
peripheral  and  central  components  in  the  function  of  the  olfactory  system.   The 
characterization of the olfactory deficit in neurodegenerative disorders—specifically in 
Parkinson’sdisease  and  parkinsonian  syndromes—has  the  potential  to  provide 
significant insights into its function in the normal and disease states, it should provide 
insight  into  the  interplay  of  different  aspects  of  central  nervous  system function  in 
neurodegeneration.
ASSESSMENT OF OLFACTORY FUNCTION
           In humans, different methods have been developed to assess distinct aspects of 
olfactory function, such as odor identification, threshold detection, and odor recognition 
memory.  A number  of  these  methods  have  achieved widespread use  of  both  in  the 
research and clinical domain.
           A commonly used test is the University of Pennsylvania Smell Identification Test 
(UPSIT),  developed  by  Doty  et  al9,10.   Its  widespread  use  is  based  on  the  case  of 
administration, the relatively short completion time and it high test – retest reliability. 
This test uses 40 odorants that are released by using a pencil to scratch the surface of a 
strip  containing a  microencapsulated odorant.   The subject  is  asked to  identify  each 
odorant by choosing among our items in a multiple-choice fashion.  A simplified version 
of UPSIT  is the CC-SIT developed by Cain and Rubin11.  In the test, odor identification 
is  combined  with  threshold  testing.   Threshold  testing  is  performed  using  plastic 
squeeze-bottles  containing  successive  dilutions  of  n-butanol  in  water,  using  4%  n-
butonal as the highest concentration.  For odor identification, the subjects sniff eight 
glass bottles containing different odorants and choose in a multiple-choice fashion from 
a uniform list of 16 items.  More recently, Hummel et al. developed a new test using a 
pen like odor-dispensing device12.  This  test assesses odor threshold (by using n-butonal 
in a stepwise presentation), odor discrimination  (16 pairs of odorants and triple-forced 
choice), and odor identification (by using 16 common odorants and a multiple forced-
choice from among four verbally stated options per odorant).  Other tests include the 
San Diego Odor  Identification test13,  the  Scandinavian Odor  Identification test14,  the 
Viennese Olfactory Test Battery15 and Smell Threshold Test16.
            Olfactory event related potentials (OERP) have been recorded in control and 
affected individuals  in response to randomized stimulation with different odorants and 
the  OERP  latencies  have  been  determined  in  control  and  affected  individuals17. 
Statstical reliability of the OERP was established by Thesen et al18, and it was shown 
that reliability  of OERPs is comparable to that of visual and  auditory evoked potentials. 
The generators for the OERP waveforms are not known.  The early waveform (PI) is 
thought to originate in the olfactory bulb and the late waveform (P3) in the olfactory 
cortex19.
             To determine whether anatomical  changes are associated with olfactory 
dysfunction, endoscopic techniques have been developed to obtain olfactory epithelium 
from  human  subjects  under  either  general  or  topical  anesthesia21,22.   The  tissue  is 
examined by light and / or electron microscopy and histochemistry23.  The usefulness of 
this procedure is limited, since it is invasive and may require general anesthesia.  The 
olfactory epithelium and the anterior olfactory nucleus can also be obtained postmortem 
and examined histologically and histochemically24.
             In summary, a number of methods are currently available to assess olfactory 
function in humans.  The choice of method depend on the ease of administration and on 
the aspect of olfactory function that is being assessed.
OLFACTORY  DYSFUNCTION  IN  NORMAL  AGING
            A number of studies have shown that olfactory dysfunction is affected by 
aging25-27.   Olfactory  impairment  associated  with  normal  aging  involves  odor 
identification, threshold detection26, and odor recognition memory28.  Olfactory function 
declines after age 65 and is severely affected after age 80.  Interestingly, in women, 
olfactory impairment appears later in men25.
           It is useful to consider olfactory dysfunction contextually in light of finding that 
the olfactory epithelium undergoes continuous regeneration throughout development and 
adult  life.   A  number  of  endogenous  and  exogenous  mechanisms  are  implicated  in 
maintaining a balance between regeneration  and degeneration.  Recently, Wu et al29. 
have shown that signals from neurons within the olfactory epithelium have the ability to 
inhibit the generation of new neurons by neural progenitors.  IN more general terms, it 
appears  that  neural  repair  of  the  mature  CNS may  be  inhibited  by  the  cellular  and 
molecular microenvironment30.  It is not clear what the role of these mechanisms is in 
aging  or  neurodegenerative  disease.   Cumulative  exposure  to  environmental  toxins, 
chemicals, upper respiratory viral infections, or head injury could contribute to gradual 
olfactory impairment by interfering with endogenous mechanism of regeneration.
    OLFACTORY  DYSFUNCTION  IN  PARKINSON’S  
                                DISEASE (PD)
           Olfactory dysfunction has been clearly demonstrated in sporadic PD. Olfactory 
dysfunction  in  this  disorder  includes  impairment  in  odor  identification,  threshold 
detection, and odor recognition memory31.  It has been shown that olfactory dysfunction 
is  present  early  in  the  disease  process  and  appears  to  remain  stable  as  the  disease 
progresses32.   Studies  have  attempted  to  correlate   olfactory  dysfunction  disease 
parameters such as disease stage, duration, subtype, cognitive dysfunction, and therapy. 
Interestingly,  olfactory  dysfunction  appears  to  be  independent  of  disease  stage  and 
disease duration32.  In contrast, olfactory dysfunction appears to be dependent on disease 
subtype,  suggesting  that  disease  subtype  confers  the  specificity  of  the  olfactory 
impairment.  In a study by Stern et al., olfactory  function was assessed in different PD 
subtypes33.  Olfactory function was more impaired in advanced PD (Hoehn and Yahr 
stage III or greater) than earlyPD (Hoehn and Yahr stage II  or less forfour or more 
years).   Both  postural  instability-gait  disorder  (PIGD)  predominant  PD  (defined  as 
UPDRS  mean  tremor  score/  mean  PIGD  score<1.0)  and  tremor-predominant  PD 
(defined as UPDRS mean tremor score/mean PIGD score<1.0 ) and tremor-predominant 
PD (defined as UPDRS mean tremor score/mean PIGD score >1.5) subtypes exhibited 
olfactory impairment, but the impairment was more severe in the PIGD form than in the 
tremor-predominant form of PD.  It is conceivable that the differences in the degree of 
olfactory  impairment  between  the  disease  subtypes  may  reflect  different 
pathophysiological  processes  in  the  two  disease  subtypes.   The  olfactory  deficits 
associated with PD appear to be independent of the cognitive dysfunction associated 
with the disease34.   Olfactory dysfunction in PD in bilateral and does not respond to 
antiparkinsonian therapy35.
           Olfactory impairment in PD has been attributed to the pathological changes, 
including neuronal  loss  and the presence  of  Lowy bodies  identified in  the olfactory 
cortex24 and the amygdala36.  Interestingly, sniffing impairment appears to contribute to 
the olfactory impairment in PD8.
    OLFACTORY   DYSFUNCTION  IN PARKINSONISM – 
                        PLUS SYNDROMES (PPSs)
          
         Olfactory function has also been assessed in multiple system atrophy (MSP), Shy-
Drager  syndrome37-38,  progressive  supranuclear  palsy  (PSP)38-39 and  the  parkinsonism-
dementia complex of Guam40. Wenning et al38 compared olfactory dysfunction in a large 
series of patients with either PD, MSA,  corticobasal degeneration (CBD),  or PSP.  They 
showed that impairment of olfactory dysfunction was significantly more pronounced in 
PD than in PPS.  In particular, olfactory impairment was mild in MSA,  whereas olfactory 
function was preserved in CBD and   PSP.  The findings from A STUDY BY Muller et al 
(2002) appear to confirm this difference in olfactory impairment between sporadic PD 
and PPS41.  This consistent difference in olfactory function can therefore be used as an aid 
in the differential diagnosis of PD and PPS.
            Olfactory dysfunction has also been reported in the ALS-parkinsonism-dementia 
complex of Guam (PDC)42.  All four forms of the syndrome (ALS,  pure parkinsonism, 
pure  dementia,  and  parkinsonism-dementia  complex)  show  impairment  of  olfactory 
function. This suggests a common mechanism of olfactory impairment in the different 
forms of the syndrome.  There are no significant differences in the degree of the olfactory 
impairment in PD and PDC, making it impossible to distinguish these two entities on the 
basis of olfactory impairment40.
            In contrast to what is seen in the sporadic forms of PPS, olfactory function is 
impaired in familial forms of PPS. Affected members Of  PPS  kindreds show impairment 
similar to that seen in kindreds with idiopathic PD (IPD) phenotypes.  Markopoulou et 
al43 assessed  olfactory  function  in  several  multigenerational  kindreds  with  an  IPD 
phenotype as well as in kindreds with a PPS phenotype.  Olfactory dysfunction appears to 
be a component of the clinical phenotype in kindreds types of kindreds.  No statistically 
significant differences in the degree of olfactory impairment were observed between these 
two phenotypes.   Thus,  it  appears that  ,  in regard to olfactory function,  sporadic and 
familial forms of PD and PPS behave differently.
              Three different genes are associated with the forms of parkinsonism assessed by 
Markopoulou et al.  One is the alpha-synuclein  gene (Family H)43, a second is the gene 
for  the  microtubule-associated  protein  tau  (pallido-ponto-nigral  degeneration,   PPND 
Family)44 and  the  third  is  an  as-yet  unidentified  gene  on  chromosome  2p1345.   The 
expression of alpha-synuclein, along with that of its congeners beta-and gama-synuclein, 
has been assessed in the olfactory mucosa of  patients with PD,  Lewy body disease, 
MSA, AD, and healthy controls46. While the synucleins are differently expressed in the 
olfactory epithelium, and alpha-synuclein is the most abundantly expressed protein, there 
is no significant difference between affected individuals and healthy controls.  However, 
it is conceivable that alpha- synculein may play a role in the regeneration of the olfactory 
epithelium.  This hypothesis is supported by other studies in which alpha- synuclein has 
been implicated in neuronal survival47-48.
              To summarize, the presence of olfactory dysfunction in familial forms of 
parkinsonism associated  with  a  monogenic  defect  suggests  that  genetic  factors  either 
directly or indirectly underlie olfactory dysfunction.
      
        OLFACTORY   DYSFUNCTION  IN  ATYPICAL 
             PARKINSONIAN  SYNDROMES  (PPSs)
               
            Olfactory function has been assessed in other atypical parkinsonian syndromes 
such as MPTP-induced parkinsonism.  In this entity, olfactory function is preserved49. 
Olfactory function is also preserved in two syndromes that may be associated with PD, 
essential tremor50-51, and idiopathic restless leg syndrome52.  While in sporadic forms of 
these syndromes, they appear to behave as independent disorders: in familial forms of 
PD, PD and essential tremor phenotypes appear to be associated at the genetic level and 
possibly reflect differential expressivity of the same monogenic defect53.
OLFACTORY  DYSFUNCTION  IN  OTHER 
NEURODEGENERATIVE  DISEASES
             Perhaps  not  surprisingly,  olfactory  function  is  impaired  in  other 
neurodegenerative  diseases  such  as  Alzheimer’s  disease  (AD)15,19,31,   motor  neuron 
disease (MND)54-56, and Huntington’s disease (HD)57-60.
            In AD, the olfactory impairment appears to occur early in the disease process61. 
Interestingly, the ApoE epsilon-4 allele, a known risk factor for AD, appears to correlate 
with  congnitive  impairment  and  odor  identification  decline62,63.   A  meta  analysis  of 
studies  of  olfactory  function  in  AD  and  PD31 suggests  that  olfactory  impairment  is 
relatively  uniform  in  these  diseases.  This  is  consistent  with  the  phenotypic  overlap 
observed in the clinical manifestations of AD and PD.  However, interesting differences 
exist  in  the  olfactory  impairment  between  AD  and  PD.   In  both  PD  and  ad,  odor 
identification is  impaired64,  but  AD patients  showed a  higher  olfactory  threshold and 
poorer odor memory performance.  In AD, olfactory impairment also appears to be a 
function of disease duration64, whereas this is not the case in PD32.  In AD, the olfactory 
bulb,  AON, piriform cortex, amygdale,  and hippocampus show neurofibrillary tangles 
and amyloid plaques65-67.   In PD, there is  neuronal loss and Lewy bodies (LB) in the 
AON.  The LB, however, resemble more the cortical than the nigral LB24.  In addition, 
there are specific changes in the amygdala of PD patients68.
            In motor neuron disease, the reports are somewhat conflicting.  Some studies 
report olfactory impairment54-55, while others do not56.  This could reflect selection bias 
and heterogeneity in the patient cohorts included in those studies.  
           In HD, the olfactory deficit is found only in affected individuals and notin gene-
positive asymptomatic individuals58.  The olfactory deficit involves primarily impairment 
of lfactory detection and odor identification but not odor recognition memory.  As in AD 
and PD, the olfactory deficit in HD appears early in the disease process59-60.
            A list of the neurodegenerative diseases associated with olfactory impairment 
associated discussed in this chapter is presented in Table.
OLFACTORY  FUNCTION  IN  NEURODEGENERATIVE    
                                   DISEASES
______________________________________________ 
Disease                                                     Olfactory function
______________________________________________________________________ Parkinson’s 
disease                                                                          Impaired
Lewy body disease                                                                           Impaired
Familial Parkinson’s disease (both IPD and PPS phenotypes)        Impaired
Progressive supranuclear palsy                                                      Preserved
Multiple system atrophy                                                      Mildly Impaired
Corticobasal ganglionic degeneration                                           Preserved
Parkinsonism-dementia of Guam                                                   Impaired
MPTP-induced Parkinsonism                                                       Preserved
Essential tremor                                             Mildly-moderately   impaired 
Alzheimer’s disease                                                                        Impaired
Motor neuron disease                                                     impaired/preserved
Huntington’s disease                                                                      Impaired
OLFACTORY  DYSFUNCTION  IN  THE  CONTEXT  OF  CURRENT 
KNOWLEDGE  OF NORMAL  OLFACTION
            The mechanism(s) underlying olfactory dysfunction in neurodegenerative diseases 
and  normal  aging  have  not  yet  been  elucidated.   However,  a  considerable  body  of 
information has accumulated over the last decade regarding the function of the olfactory 
system at the molecular, cellular, and system levels, both  at the periphery and centrally. 
While several aspects of olfactory system function remain a mystery, amore complete 
understanding of the complex organization of the olfactory system is emerging from these 
analyses.
           We now know that in the periphery, olfaction is initiated by binding of an odorous 
ligand  to  the  Ors  that  are  expressed  in  olfactory  neurons  (ORN),  located  within  the 
olfactory epithelium.  The ORs reflect the first organizational level at which specificity is 
established, as each neuron expresses only one receptor type.  The spatial organization of 
the neurons  that  express  one type of  receptor  in  the olfactory epithelium reflects  the 
second  organizational  level  at  which  specificity  is  established.   The  third  level  of 
organization  occurs  at   the  olfactory  bulb  where  the  second-order  neurons  from 
connections in specific stereotypic sites in the olfactory bulb.  The axons of first order 
neurons  from the heterogeneous  fascicles  that  defasciculate  in  the olfactory bulb and 
refasciculate with neurons expressing the same OR.  Both permissive and inhibitory cues 
may contribute to this organizational process.  This axon targeting may constitute another 
level of organization.  Finally, behaviorally induced plasticity in the olfactory bulb may 
add yet another level of organizational complexity69.  It will be important to understand 
whether the neurodegenerative process affects one or more levels of organization and the 
associated functions of the olfactory system
           Since the establishment of an association of olfactory dysfunction with PD and 
other neurodegenerative diseases,  two broadly crafted,  alternate hypotheses have been 
proposed  to  account  for  the  nature  of  the  olfactory  deficits.   According  to  the  first 
hypothesis,  the  observed olfactory  impairment  is  due  to  peripheral  processes  such as 
environmental insults to the olfactory system.  According to the second hypothesis, the 
olfactory impairment is due to central processes.  Support for the second hypothesis is 
provided by the the fact  that  in both PD and AD the olfactory system appears to be 
affected in a disease-specific manner.   In patients with autopsy-proven PD, the AON 
contains dystrophic neuritis and Lewy bodies (LBs).  These LB are morphologically more 
similar to cortical than to nigral LB70.  In addition, there is considerable neuronal loss in 
the AON.  The degree of neuronal loss correlates strongly with the disease duration24. 
This  is  in  apparent  contradiction  with  the  observation  that  olfactory  dysfunction  is 
independent  of  disease  duration  in  PD.   In  AD,  neurofibrillary  tangles  and  amyloid 
plaques are seen in the AON.  PD-specific pathology is also observed in the amygdala68. 
The amygdala is part of the limbic system and forms a large number of connections with 
the hippocampus and the entorhinal cortex as well as the neocortex.  It is involved in 
memory , behavior, and regulation of endocrine and autonomic function and olfaction.  In 
the amygdale, the neuropathological changes appear to accumulate slowly over time as 
the disease progresses.  However, in PD patients, the severity of amygdale involvement 
appears to be independent of cognitive deficits68.
             Furthermore, the olfactory bulb is rich in dopamine neurons, and a physiological 
role for dopa in the olfactory bulb has been demonstrated in the rat olfactory system. 
Dopamine suppresses the electrical activity of mitral cells71, and the olfactory bulb is rich 
in dopamine receptors (both D1 and D2).  In the olfactory bulb, there is a differential 
distribution pattern of the dopamine receptors72.  Recently, it has been demonstrated that, 
in  the  rat  olfactory  bulb,  dopamine  receptor  subtypes  can  modulate  the  response  of 
GABA A  receptors and could be instrumental in odor detection, odor discrimination, and 
olfactory learning73.  Interestingly, in clinical studies, the olfactory dysfunction observed 
in PD appears not to be a manifestation of dopamine deficiency74.  Olfactory function was 
assessed in a small series of hyposmic PD patients before and after the administration of 
apomorphine, apotent, short acting dopamine agonist, and no difference was observed. 
While the number of parkinsonian individuals tested in the study was small, the fact that 
olfactory dysfunction appears to be independent of disease stage or duration32  provides 
indirect support for this hypothesis.  However, this may be explained by the fact that the 
early  appearance  of  symptoms  of  olfactory  dysfunction  may  reflect  a  threshold 
phenomenon that is achieved earlier in the olfactory system than in other areas of the 
CNS.
              The complexity of the olfactory system’s organization and its extensive 
connections  to  many  cortical  regions,  the  basal  ganglia,  and  cerebellum suggest  that 
defects in any of a number of different molecular, cellular, or physiological processes 
may lead to olfactory dysfunction at the level of odor discrimination, recognition, and 
memory.   In  humans,  many  olfactory  receptors  genes  (approximately  72%)  are 
nonfunctional  and  are  distributed  on  nearly  all  chromosomes.   A  large  number  of 
olfactory  receptor  genes  are  found  in  telomeric  chromosomal  regions75.   Given  the 
association of telomere length with senescence76 as well  as  the known association of 
olfactory dysfunction with aging, it is tempting to speculate that the telomeric location of 
OR genes may make them more prone to deletion / inactivation that may in turn lead to 
age-dependent olfactory dysfunction.  It is unclear whether such a process might play 
arole  in  the  mechanisms  underlying  olfactory  dysfunction  associated  with  PD  and 
neurodegenerative diseases.
              System level approaches have provided a valuable perspective on the central 
mechanisms in the development and function of the olfactory system.It is thought that the 
brain can determine which neurons are excited by analyzing a topographic map in the 
olfactory bulb78.Activity dependent mechanisms and stimulus specific synchronization of 
neuronal groups may be involved in olfactory processing79,80.Network dynamics can also 
be instrumental by creating odour representation and optimizing their distribution.Both 
slow,nonperiodic processes and fast,oscillatory processes may contribute to the coding 
that is inherent in the olfactory system81.It will be important to understand whether and 
how these central mechanisms are altered in neurodegenerative disease.
                           
              CONCLUSIONS OF LITERATURE STUDY
             The olfactory system is a complex network whose organization and function 
depends on both peripheral and central input. It is commonly affected in Parkinson’s 
disease (PD),  parkinsonism – plus syndromes (PPS), other neurodegenerative disorders 
(e.g., Alzheimers’s disease ,(AD)),  and in normal aging.  Olfactory dysfunction usually 
appears early in the disease process.  IN PD, olfactory function is commonly impaired 
whereas, in PPS, olfactory function is only mildly impaired or preserved.  Olfactory 
function  is  also  impaired  in  familial  forms  of  parkinsonism  associated  with  a 
monogenetic defect.  In contrast to individuals with sporadic PPS, affected members of 
PPS kindreds do show olfactory impairment.  Interestingly, olfactory dysfunction does 
not appear to be due to dopamine deficiency.  The neuropathological changes in the 
olfactory system appear to be disease specific.  This suggests that olfactory dysfunction 
in neurodegenerative disorders may reflect a central rather than a peripheral process. 
The organization of the normal olfactory system is gradually being elucidated at the 
molecular, cellular, and system levels.The mechanisms underlying olfactory dysfunction 
in PD and other neurodegenerative diseases remain unknown.
       
                          FUTURE DIRECTIONS
              The study of the olfactory system in neurodegeneration offers a unique arena in 
which  to  employ  a  combination  of  analytical  approaches  at  the  molecular,cellular, 
physiological, and system levels.  This uniqueness is not system-specific but rather, the 
result of simultaneous advances in many scientific fronts.  An important advance is the 
identification of the primary genetic defect in a number of neurodegenerative disorders. 
Another important advance is the development of genomic and proteomic analyses in 
which the simultaneous expression of thousands of genes in different tissues including 
brain tissue can be analyzed (e.g., using microarrays).  Another advance is the analysis 
of  the  olfactory  system by a  dynamical  system approach  that  has  led  to  significant 
insights into the organization and complexity of olfactory system.  Finally, the advent of 
functional  imaging,  including  fMRI  and  PET,  allows  the  in  vivo  functional 
characterization  of  olfaction  and  related  higher  cognitive  processes  in  normal  and 
diseased  states.   Understanding  how  the  olfactory  system  is  affected  by 
neurodegeneration will require a synthesis of these conceptually different approaches. 
The field is in a particular moment in its development that a synthesis will open up new 
insights into both the functional understanding of the olfactory system as well as the 
neurodegenerative process.
                    
                         AIMS OF THE STUDY
1) To assess the presence and the extent of  olfactory impairment in various types  of 
parkinsonian patients.
2) To assess the correlation between extent of olfactory dysfunction and the 
duration&severity of the disease  in various types of parkinsonism.
3) To assess the practical use of olfactory function tests in supplementing the diagnosis 
of various parkinsonian syndromes
4) To assess any  impact of  DOPA therapy on olfactory impairment in various types    of 
parkinsonism.
                  
      
                         
MATERIALS AND METHODS
          This study was conducted among patients with various types of parkinsonism 
coming to  outpatient clinic and in-patients of  Institute of  Neurology,Chennai over the 
period of  2 ½ years from Oct 2005 to March 2008. Seventy patients suffering from 
various types of  parkinsonism  were selected for  olfactory functions tests  in order  to 
assess the presence and extent of olfactory dysfunction at various stages &duration of the 
illness  and  to  analyse  whether  treatment  will  cause  any  change  or  improvement  in 
olfactory functions.
                       
INCLUSION CRITERIA  
1) The patients who were presented with hypokinesia,rigidity with or without tremor in 
the age group of 20-75 years were included in this study.
2) Those patients who are having early signs and symptoms of  parkinsonism within 5 
years of duration of illness are included.
3) Patients  with idiopathic   parkinsonism,Progressive supranuclear  palsy,Multi  system 
atrophy,Familial  parkinsonism,spinocerebellar atrophy presenting with parkinsonism 
and vascular parkinsonism are included.
 
EXCLUSION CRITERIA    
1) Parkinsonian patients  with more than 5 years duration of illness were excluded in 
order  to avoid the confusion arising  due to the presence of  olfactory dysfunction 
commonly in late stages of parkinsonism of all types.
2) Patients  with  severe  cognitive  dysfunction&dementia  were  excluded  because  they 
cannot respond sensitively to the olfactory function tests and since the correct odour 
identification depends on the intact odour memory.
3) Patients with chronic upper respiratory tract infection like sinusitis,nasal polyp were 
excluded.
4) Patients  with  aphasia  and  parkinsonism  were  excluded  because  they  will  find  it 
difficult to tell their inferences of  olfactory function tests.
5) Patients  >75  years  of  age  were  excluded  because  of  the  diminution  of  olfactory 
functions evolving naturally in old age people.
6) Parkinsonism  due  to  secondary  causes  like  Wilson’s  disease,Hallevordenspatz 
disease,Neuronal degeneration due to brain iron accumulation,Huntington’s disease, 
some mitochondrial diseases presenting with parkinsonism,neuroleptic drug induced 
parkinsonism and parkinsonism with florid psychiatric manifestations  were excluded
          
         A  total of 70 cases of parkinsonism belonging to various subtypes were selected 
according  to  the  inclusion&exclusion  criteria,thoroughly  examined  clinically  and 
investigated  with  blood  chemistry  and  CT&MRI  scans.Patients  with  idiopathic 
parkinsonism are categorized according to UPDRS scoring and Modified Hoehn&Yahr 
staging. 
               All the 70 patients are analysed by  1) odour identification test,  2)odour 
discrimination  Test & 3)odour threshold test. This prospective observational study was 
done serially once in 3 months for every patient for  a total period of one year.
        The odourous substances used in this study are the following
1)coffee  powder  2)Tea  powder  3)Camphor  4)Tobacco  powder  5)Asafoetida  6)Pepper 
powder 7)coriander leaves(mashed) 8)eucalyptus oil  9)jasmine flowers 10)Rose petals 
11)antiseptic spirit  and 12)naphthalene balls.
         Only 12 odorous substances were used in order to simplify the testing and to reduce 
the time taken to complete the entire olfactory testing. 
         Every patient was instructed to close both eyes and asked to sniff gently the given 
odorous substance kept in a small bowl in each nostril separately by closing the other 
nostril.One minute time was given to identify the odour and the patient was asked to 
choose the correct item from the 4 written answers.
   If the patient identified >10 substances-normal.8-10(mild olfactory dysfunction) 
5-7(moderate olf.dysfunction),0-4(severe olf.dysfunction)
Sl.no Scoring of the  Olfactory 
dysfunction
Number of odourous substances 
identified (Out of 12 substances)
1 Mild             8-10
2 Moderate             5-7
3 Severe             0-4
       Odour discrimination test was performed bygiving 2 different odourous substances 
and third odour  similar  to  the  first  odourous  substance  and the  patient  was  asked to 
differentiate the odours correctly.
        
Odour  threshold  testing  was  performed by giving  various  dilutions  of   n-butyl 
alcohol starting from low dilutions to slowly increasing dilutions(upto 4% max.dilution) 
and the dilution of  alcohol at which patient starts to appreciate the odour was identified. 
       
The presence&severity of olfactory dysfunction was analysed in various subtypes 
of parkinsonian patients and was correlated with different stages of parkinsonism and 
duration of illness.
      New patients  with Idiopathic  parkinsonism,  Multiple  system atrophy and 
Progressive supranuclear palsy were started on adequate dopa therapy and the old patients 
were maintained on their previous treatment schedule(dopa and anticholinergics).
                  
Modified Hoehn and Yahr staging of Parkinson’s disease                          
Stage 0-no signs of the disease
Stage 1-Unilateral disease
Stage 1.5-Unilateral plus axial involvement
Stage 2-Bilateral disease,without impairment of balance
Stage 2.5-Mild bilateral disease with recovery on pull test
Stage3-Mildto  moderate  bilateral  disease,some  postural  instability,physically 
independent
Stage 4-Severe disability,still able to walk or stand unassisted
Stage  5-Wheel chair bound or bedridden unless aided.
    
        
Unified Parkinson’s Disease Rating Scale (UPDRS)
         The UPDRS is a rating tool to follow the longitudinal course of Parkinson's 
Disease. It is made up of the 1) Mentation, Behavior and Mood  2)ADL and 3) Motor 
sections.  These  are  evaluated  by  interview.  Some  sections  require  multiple  grades 
assigned to each extremity. A total of 176 points  are possible.176  represents the worst 
(total) disability),                                                                   0—no disability.
I.  Mentation, Behavior & Mood 
  Intellectual Impairment
       0-none.
       1-mild (consistent forgetfulness with partial recollection of events)                        
       2-moderate memory loss with disorientation and moderate difficulty handling 
complex problems.
       3-severe memory loss with disorientation to time and often place,  severe 
impairment with problems.
       4-severe memory loss with orientation only to person, unable to make judgments or 
solve problems.
    
Thought Disorder 
         0-none
       1-vivid dreaming
       2-"benign" hallucination with insight retained
       3-occasional to frequent hallucination or delusions without insight      
       4-persistent hallucination, delusions, or florid psychosis.
  Depression
       0-not present
       1-periods of sadness or guilt greater than normal, never sustained 
more than  a few days or a week
       2-sustained depression for >1 week
       3-vegetative symptoms (insomnia, anorexia, abulia, weight loss)
       4-vegetative symptoms with suicidality
   Motivation/Initiative
       0-normal
       1-less of assertive, more passive
       2-loss of initiative or disinterest in elective activities
       3-loss of initiative or disinterest in day to say (routine) activities
       4-withdrawn, complete loss of motivation
II.  Activities of Daily Living 
Speech
       0-normal
       1-mildly affected, no difficulty being understood
       2-moderately affected, may be asked to repeat
       3-severely affected, frequently asked to repeat 
       4-unintelligible most of time
 Salivation
       0-normal
       1-slight but noticeable increase, may have nighttime drooling
       2-moderately excessive saliva, hay minimal drooling
       3-marked drooling
   Swallowing
       0-normal
       1-rare choking
       2-occasional choking
       3-requires soft food
       4-requires NG tube or G-tube
   Handwriting
       0-normal
       1-slightly small or slow
       2-all words small but legible
       3-severely affected, not all words legible
       4-majority illegible
   Cutting Food/Handing Utensils
        0-normal
       1-somewhat slow and clumsy but no help needed
       2-can cut most foods, some help needed
       3-food must be cut, but can feed self     
        4-needs to be fed
  
  Dressing 
         0-normal
       1-somewhat slow, no help needed
       2-occasional help with buttons or arms in sleeves
       3-considerable help required but can do something alone
       4-helpless
   Hygiene
       0-normal
       1-somewhat slow but no help needed
       2-needs help with shower or bath or very slow in hygienic care
       3-requires assistance for washing, brushing teeth, going to bathroom
       4-helpless
 Turning in Bed/ Adjusting Bed Clothes  
       0-normal
       1-somewhat slow no help needed
       2-can turn alone or adjust sheets but with great difficulty
       3-can initiate but not turn or adjust alone
       4-helpless  
 Falling-Unrelated to Freezing
         0-none
       1-rare falls
       2-occasional, less than one per day
       3-average of once per day
       4->1 per day
 Freezing When Walking
       0-normal
       1-rare, may have start hesitation
       2-occasional falls from freezing 
       3-frequent freezing, occasional falls
       4-frequent falls from freezing
 Walking
       0-normal
       1-mild difficulty, day drag legs or decrease arm swing
       2-moderate difficultly requires no assist
       3-severe disturbance requires assistance
       4-cannot walk at all even with assist
    Tremor
       0-absent
       1-slight and infrequent, not bothersome to patient
       2-moderate, bothersome to patient
       3-severe, interfere with many activities
       4-marked, interferes with many activities
 Sensory Complaints Related to Parkinsonism
          0-none
        1-occasionally has numbness, tingling, and mild aching
       2-frequent, but not distressing
       3-frequent painful sensation
       4-excruciating pain
III.  Motor Exam
 Speech
       0-normal
       1-slight loss of expression, diction,volume
       2-monotone, slurred but understandable, mod. impaired
       3-marked impairment, difficult to understand
       4-unintelligible
 Facial Expression
       0-Normal
       1-slight hypomymia, could be poker face
       2-slight but definite abnormal diminution in expression
       3-mod. hypomimia, lips parted some of time
       4-masked or fixed face, lips parted 1/4 of inch or more 
 *Tremor at Rest 
  Face 
         0-absent
         1-slight and infrequent
         2-mild and present most of time
         3-moderate and present most of time
         4-marked and present most of time
Right Upper Extremity &Left upper extremity 
         0-absent
         1-slight and infrequent
         2-mild and present most of time
         3-moderate and present most of time
         4-marked and present most of time 
Right lower extremity&Left lower extremity
         0-absent
         1-slight and infrequent
         2-mild and present most of time
         3-moderate and present most of time
         4-marked and present most of time
*Action or Postural Tremor
 Right upper extremity&Lt upper extremity
         0-absent
         1-slight, present with action
         2-moderate, present with action
         3-moderate present with action and posture holding
         4-marked, interferes with feeding
 *Rigidity
  Neck
         0-absent
         1-slight or only with activation
         2-mild/moderate
         3-marked, full range of motion
         4-severe 
  Right upper extremity&Left upper extremity
         0-absent
         1-slight or only with activation
         2-mild/moderate
         3-marked, full range of motion
         4-severe
 Right lower extremity&Left lower extremity
         0-absent
         1-slight or only with activation
         2-mild/moderate
         3-marked, full range of motion
         4-severe
  *Finger taps
    Right&Left finger taps
         0-normal
         1-mild slowing, and/or reduction in amp.
         2-moderate impaired. Definite and early fatiguing, 
         3-severely impaired. Frequent hesitations and arrests.
         4-can barely perform
  *Hand Movements (open and close hands in rapid  succession)     
   Right & Left  hand movements
          0-normal
         1-mild slowing, and/or reduction in amp.
         2-moderate impaired. Definite and early fatiguing 
3)severely impaired. Frequent hesitations and arrests.
         4-can barely perform
 *Rapid Alternating Movements (pronate and supinate hands)
 Right&Left hands
         0-normal
         1-mild slowing, and/or reduction in amp.
         2-moderate impaired. Definite and early fatiguing, 
         3-severely impaired. Frequent hesitations and arrests.
         4-can barely perform
*Leg Agility (tap heel on ground, amp should be 3 inches) 
 Right&Left leg
         0-normal
         1-mild slowing, and/or reduction in amp.
         2-moderate impaired. Definite and early fatiguing, 
         3-severely impaired. Frequent hesitations and arrests.
         4-can barely perform
*Arising From Chair 
         0-normal
       1-slow, may need more than one attempt
       2-pushes self up from arms or seat
       3-tends to fall back, may need multiple tries but can arise without assistance
       4-unable to arise without help
 *Posture
       0-normal erect
       1-slightly stooped, could be normal for older person
       2-definitely abnormal, mod. stooped, may lean to one side
       3-severely stooped with kyphosis
       4-marked flexion with extreme abnormality of posture
 *Gait
    0-normal   1-walks slowly,may shuffle with short steps,no festination 
   2-walks with difficulty, little or no assistance, some festination, short steps    
   3-severe disturbance, frequent assistance
   4-cannot walk
 *Postural Stability (retropulsion test)
       0-normal
       1-recovers unaided
       2-would fall if not caught
       3-falls spontaneously
       4-unable to stand
 *Body Bradykinesia/ Hypokinesia
       0-none
       1-minimal slowness, could be normal, deliberate character
       2-mild slowness and poverty of movement, definitely abnormal
       3-moderate slowness, poverty, or small amplitude
       4-marked slowness, poverty, or amplitude
Grades of UPDRS scoring
Mild disease-score 1-31
Moderate disease  score 32-62
Severe disease   63-176
RESULTS OF THE STUDY
     Out  of 70 patients with parkinsonism, 52 patients were males,18 patients were 
females.51  patients  are  of  Idiopathic  parkinsonism,5patients  are  of  Multiple  system 
atrophy,4  patients  are  of  Progressive  supranuclear  palsy,6  patients  are  of  vascular 
parkinsonism,2patients  are  of  Spinocerebellar  ataxia  and  2  patients  are  of  familial 
parkinsonism.
      Number of patients with various subtypes of parkinsonism studied
Type of Parkinsonism Male Female Total Percentage(out 
of 70 patients)
1 Idiopathic Parkinsonism 39 12 51 72.8%
2 Multi system Atrophy 3 2 5 7%
3 Prog. supranuclear palsy 2 2 4 5.5%
4 Vascular Parkinsonism 4 2 6 8.6%
5 Familial Parkinsonism 2 0 2 2.9%
6 SCA(with parkinsonism) 2 0 2 2.9%
      Total 52 18 70 100%
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1 Idiopathic 
Parkinsonism
    --      --     9    14    19     9
2 Multisystem 
Atrophy
    --      --     3     2     --     --
3 Progressive 
supranuclear palsy
    --      --     3     1     --     --
4 Vascular 
Parkinsonism
    --      --     --     1     3     2
5 Familial 
Parkinsonism
    --      1     1     --     --     --
6 SCA(with
parkinsonism)
   2      --     --     --     --     --
Total(70 patients)    2     1     16     18     22     11
     Patients with parkinsonism presented at various duration of illness
Types of Parkinsonism 1st yr 2nd yr 3rd yr 4th yr 5th yr
1 Idiopathic Parkinsonism     24     14      7      6      --
2 Multi system Atrophy       3      1      1       1
3 Progressive supranuclear 
palsy
      1      --      1      2      --
4 Vascular Parkinsonism       2       3      1      --      --
5 Familial Parkinsonism       --       1      1      --      --
6 SCA(with parkinsonism)       --      --      --      1      --
      Total    27    21    11    10     1
            UPDRS scoring of Idiopathic Parkinsonism patients
Mild(1-31score) Moderate(32-62score) Severe(63-176score)
male Female male female Male female
26 8 10 3 3 1
Total             34                13                      4
Number of patients with idiopathic parkinsonism(Hoehn&Yahr staging)
Hoehn&Yahr staging Male Female Total
1 Stage 1 6 3 9
2 Stage 1.5 5 1 6
3 Stage 2 11 3 14
4 Stage 2.5 4 1 5
5 Stage 3 10 3 13
6 Stage 4 3 1 4
7 Stage 5 0 0 0
Net results of olfactory function tests in various types of parkinsonism patients
Types of Parkinsonism Total 
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1 Idiopathic parkinsonism 51 51 51   51 100%
2 Multisystem atrophy 5 2 2    0 40%
3 Prog.supranuclear palsy 4 0 0     0 0%
4 Familial parkinsonism 2 2 2     2 100%
5 Vascular parkinsonism 6 0 0     0 0%
6 SCA 2 0 0      0 0%
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Results of olfactory functions tests in idiopathic parkinsonism patients
                          (categorized according to UPDRS scoring)
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1 Mild disease
(out of 34patients)
         0
        
           21            13      34      34
2 Moderate disease
(outof13patients)
          0            7            6      13      13
3 Severe disease
(out of 4patients)
          0            0            4       4       4
  
Total           0             28            23        51 51
    Results of olfactory function tests in idiopathic parkinsonism patients    
                                (categorized by   Hoehn & Yahr staging)
Hoehn&Yahr staging               Olfactory  function  impairment
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4 Stage 2.5 (5patients) 0          2         3           5          5    
5 Stage 3   (13patients) 0          7         6          13          13
6 Stage 4 (4patients) 0          0         4          4          4
7 Stage 5 (0 patients) 0          0         0          0          0
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Gross results of olfactory function tests in various types of parkinsonism patients 
Olfactory 
tests
I.P MSA PSP V.P F.P SCA
1 Odour 
identification
severely
Impaired
Mildly
impaired
Normal Normal Moderately
Impaired
Normal
2 Odour 
discrimination
severely
Impaired
Mildly 
impaired
Normal Normal Moderately
Impaired
Normal
3 Odour 
threshold 
elevated normal Normal Normal elevated Normal
I.P-Idiopathic Parkinsonism,MSA-Multisystem atrophy,PSP-Progressive supranuclear 
palsy,V.P-Vascular parkinsonism,F.P-Familial parkinsonism,SCA-Spinocerebellar 
ataxia
 
RESULTS OF THE OLFACTORY FUNCTION TESTS
  
            Out of 70 patients with parkinsonism tested in this study,51patients (72.8%)are of 
idiopathic parkinsonism,5patients(7%) are of MSA,4patients(5.5%) are of PSP,6patients 
(8.6%)are of vascular parkinsonism,2patients(2.9%) are of familial parkinsonism and 2 
patients(2.9%)  are  of  SCA.Among  70  patients  studied,52  are  males,18  are  females 
making M:F ratio almost 3:1.
    
1) In 51patients with idiopathic parkinsonism,Odour identification test showed that 28 
patients  had  moderate  olfactory  dysfunction,23  patients  had  severe  olfactory 
dysfunction and all 51 patients also had impaired odour discrimination and elevated 
oduor threshold.
2) 24 patients presented themselves  in the first year of their illness.Among these pts,7 
patients  have  already  severe  olfactory  dysfunction  and  17 patients  had  moderate 
olfactory dysfunction.Out of 14 pts presented in 2nd year of their illness,6patients had 
severe olfactory dysfunction,8patients had moderate olfactory dysfunction.Out of 7 
pts presented in 3rd year of  illness,5 patients had severe and 2 patients had moderate 
olf.dysfunction.Out of 6 patients presented in 4th year of illness,5 patients  had severe 
olf.dysfunction and one patient had moderate olf.dysfunction.
3) In 51  idiopathic parkinsonian patients, 6 patients showed strictly unilateral signs in 
the form of tremor and rigidity,22patients showed bilateral but asymmetrical signs 
and the remaining 23 patients showed bilateral symmetrical signs.But all 51patients 
had bilateral olfactory impairment irrespective of the asymmetrical signs in many of 
them.
4) In 5 MSA patients,2 patients(one presented at 4th year and another presented at 5th 
year of illness)had mild olf.dysfunction.
5) Out of  2 familial parkinsonism patients,One presented at 2nd year of illness had mild 
olf.dysfunction  and  the  other  presented  at  3rd year  of  illness  had  moderate 
olf.dysfunction
6) In  all  PSP(4  patients),Vascular  parkinsonism(6  patients)  and  SCA(2patients) 
cases,None had olfactory dysfunction.
     All newly diagnosed patients were started on L.Dopa and anticholinergics therapy 
and the  dopa therapy given to  the  already diagnosed patients  were maintained with 
minimal modifications of dosage if needed. 
        Periodical followup olfactory function tests of all patients were done at every 3 
months for a minimum period of one year.
The results of olfactory function tests at the end of one year.
                                
         1)In Idiopathic parkinsonism patients,out of 28 patients with moderate olfactory 
dysfunction,16 patients  deteriorated further to have severe olfactory dysfunction inspite 
of continued Dopa therapy.These 16 patients have deteriorated further in the severity of 
the  illness  (fromH&Y  staging2-2.5  to  3-4).Those  patients  with  severe  olfactory 
dysfunction(23 patients) continued to have severe olf.dysfunction inspite of  treatment 
with L.Dopa.
Changes in olfactory impairment of Idiopathic Parkinsonism patients in the  followup 
study  after one year
                                                
Severity of 
olf.dysfunction
Initial observations Followup after one year
H&Y 
staging
number
    of
patient
Total 
number 
of 
patient
H&Y 
staging
Number
   of
patients
Total 
number 
of 
patient
Moderate olfactory
dysfunction
Stage 1
Stage1.5
Stage2
Stage2.5
Stage3
Stage4
4
6
12
6
0
0
28 Stage1
Stage1.5
Stage2
Stage2.5
Stage3
Stage4
1
3
3
5
0
0
12
Severe olfactory 
dysfunction
Stage1
Stage1.5
Stage2
Stage2.5
Stage3
Stage4
0
0
0
0
16
7
23 Stage1
Stage1.5
Stage2
Stage2.5
Stage3
Stage4
0
0
0
0
26
13
39
2) Out  of  2  patients  with  familial  parkinsonism,One  patient  who  had  mild 
olf.dysfunction worsened to have moderate olf.dysfunction at the end of one year 
inspite of Dopa therapy and the other patient who had moderate olf.dysfunction 
earlier remained static as before.
  
3) Out of 5 patients with MSA,the two patients who had mild olfactory dysfunction 
continued  to  have  mild  olf.dysfunction  inspite  of   further  worsening  of  their 
illness and the three patients 
0
5
10
15
20
25
30
35
40
Initial
observations
followup
after one
year
moderate
olf.dysfn
severe
olf.dysfn
Olfactory dysfunction after one year followup in Idio.parkin pts
compared with initial observations
Severity of olfactory dysfunction
Nu
m
be
r o
f p
ati
en
ts
         who  didn’t  have  any  olf.dyfunction  earlier  continued  to  have  normal 
olf.dysfunction at the end of one year.
4) In  all  patients  with  PSP,SCA,Vascular  parkinsonism  who  participated  in  this 
study(PSP-4cases,SCA-2cases,Vascular  parkinsonism-6cases),whose  olfactory 
functions were normal at the beginning of the study remained so at the end of one 
year.                               
   
      
DISCUSSION
1) The results of the olfactory function tests done in 70 patients with various  types 
of   Parkinsonism showed  that  all   patients  with  idiopathic  parkinsonism had 
moderate  to  severe  olfactory  dysfunction  in  the  form  of  impaired  odour 
identification & discrimination and elevated odour threshold.These observations 
are similar to the results shown by Mesholam et al study31(1987).
2) The study results showed that olfactory impairment is more severe in later stages 
of parkinsonism(H&Ystage 3-5)(UPDRS score63-176).The severity of olfactory 
impairment  is not depending on the duration of illness because 7 patients had 
severe olfactory impairment in their first year of illness itself with disease severity 
ranging from H&Y stage3-4 and 17 patients had moderate olfactory impairment 
in their first year of illness with disease severity ranging from H&Y stage 1-2.5.It 
shows clearly that in Idiopathic parkinsonism patients,the olfactory impairment 
already  exists  very  early  in  the  disease  course  and  the  severity  of  olfactory 
impairment worsens further  in H&Y stages 3-4.These observations are exactly 
similar to the results shown by Doty et al32 and  Stern et al33  study where it was 
observed that olfactory dysfunction is independent of the disease duration and is 
more impaired in advanced Parkinson’s disease(H&Y stage3 or more).
3) Doty9,10 and  Hawkes  et  al70 found  out  in  their  studies  that  70-100% of  their 
patients with idiopathic parkinsonism had olfactory impairment thus making this 
as  common  a  clinical  sign  as  a  pill  rolling  rest  tremor.In  this  study,all  51 
patients(100%)of   idiopathic  parkinsonism  had  moderate  to  severe  olfactory 
impairment that too many of them had it in their early phases of  illness.
4) Stern  and  Doty  et  al35 found  out  that  the  olfactory  impairment  in  idiopathic 
parkinsonian patients occurs bilaterally even when motor signs are asymmetrical 
or unilateral and it is independent of anti parkinsonian medication and does not 
vary between the “on-off” state in Dopa treated patients.In this study,out of 51 
idiopathic parkinsonian patients, 6 patients had strictly unilateral signs in the form 
of tremors and rigidity and 22 patients had bilateral  asymmetrical  signs but all of 
them had bilateral olfactory impairment and the olfactory tests conducted at the 
“on-off”  state  due  to  dopa  therapy  in  some  of  these  patients  showed  same 
olfactory  impairment  in  these  two  states  without  any   changes.  All  these 
observations correlates well with findings made out by Stern and Doty et al.
           
5) In the followup study,16 patients had further worsening of olfactory impairment 
(from  moderate  to  severe)  with  worsening  of  severity  of  the  illness.In  the 
remaining 12 patients who had the same moderate olfactory impairment after one 
year,the  disease  severity  has  not  changed.It  again  clearly  indicates  the  more 
worsening  of  olfactory  impairment  occurs  in  the  later  stages  of  idiopathic 
parkinsonism( H&Y staging 3-5) irrespective of duration of the disease.  Also the 
study  results  showed  that  there  is  no  improvement  observed   in  olfactory 
functions after L.Dopa therapy. Doty and Stern et al35study showed similar results.
         
So the olfactory dysfunction in Idiopathic parkinsonism patients is not dependent 
on disease duration and therapy but it is present in the early stage of  the illness 
and is more severe in late stages of the parkinsonism.
 
6) In 2 cases of Familial parkinsonism(all other secondary causes of parkinsonism 
were ruled out),there are moderate olfactory dysfunction with disease severity for 
one  person  H&Y  stage  2.5  and  for  another  stage3.Unfortunately,it  was  not 
possible to test  olfactory functions in all  the  family members due to the non 
reporting of the family members to the hospital inspite of  repeated requests.The 
observations  made  in  familial  parkinsonism patients  are  similar  to  the  results 
shown in Markopoulou et al study43,44.
          
7) In  5  MSA  cases  studied,2  cases  had  mild  olfactory  dysfunction  when  they 
presented at 4th and 5th year of their illness with the disease severity of H&Y stage 
3  and  4  respectively.One  year  followup  study  showed   there  was  no  further 
worsening  of  olfactory  dysfunction  inspite  of  increasing  disease  severity.The 
remaining  cases  did  not  show  any  olfactory  dysfunction  even  after  one  year 
followup inspite  of  worsening illness.Muller  et  al41study(2002)  showed similar 
results in MSA group of patients. 
  
8) In  4  cases  of  PSP,6  cases  of  Vascular  parkinsonism  and  2  cases  of 
SCA(SCA1&SCA3  presenting  with  parkinsonism),None  had  olfactory 
dysfunction.Even  after  one  year  followup,none  developed  olfactory 
dysfunction.These observations are similar to the results shown by Wenning and 
Doty et al38,39 study done in atypical parkinsonism patients.
        
Based  on  the  above  study  results,one  can  be  definite  to  diagnose  idiopathic 
parkinsonism even  at  the  earliest  stage  of   the  disease  when  the  diagnosis  is 
doubtful,if the patient is found out to have significant olfactory impairment.
                           
                                    
                             CONCLUSIONS
Significant  olfactory  impairment  is  present  even  in  early  stages  of  idiopathic 
parkinsonism
1) Odour identification and odour discrimination are both impaired and odour threshold 
is elevated  in idiopathic parkinsonism.
2) Olfactory impairment is severe in later stages of Idiopathic parkinsonism.
3) The severity of olfactory impairment is not dependent on the duration of illness but 
dependant on the disease stage(Hoehn&Yahr staging and UPDRS scoring)
4) In  doubtful  early  clinical  presentation  of  parkinsonism,presence  of  significant 
olfactory impairment suggests the possibility of Idiopathic parkinsonism.
5) Dopa  therapy  does  not  alter  the  presence  or  severity  of  olfactory  impairment  in 
various subtypes of parkinsonism.
6) In Familial parkinsonism,olfactory functions are impaired.
7) In Multi  system atrophy,olfactory functions are  impaired mildly in  late  stages  of 
illness.
               In Progressive supranuclear palsy,Vascular parkinsonism, 
          Spinocerebellar ataxia presenting with parkinsonism,olfactory 
          functions are not impaired.
8) Olfactory function tests can be used as an easy bedside supplementary clinical tool in 
the diagnosis of various subtypes of parkinsonism.
              
 
                              
                                 PROFORMA FOR EVALUATION
                
                   The seventy patients who were presented with hypokinesia,rigidity with or 
without tremors were thoroughly examined clinically according to the proforma given 
below.
Name                        Age                      sex                                occupation
Complaints                                                                                   Duration    
Present History 
Slowness of activities     Tendancy to fall           Tremors of hands/body/head  
Laterality of symptoms(uni or bilateral)                 
Cognition level                  Emotional attitude                         speech difficulty
Symptoms  of   associated   systems    involvement  
Pyramidal                                     cerebellar                                      autonomic
Duration of each&every symptom  
Past   History
    Hypertension                        Exposure to industrial toxins,pesticides,CO
    Diabetes                                            Smoking
    Hyperlipidaemia                             Alcoholism,Psychosis&Treatment
    Previous strokes                              Family history of similar illness
    Head injury                                 Sinusitis(to do olfactory function tests)
Clinical examination
 Higher mental functions
     Cognition level              Speech                                         Apraxia
     Memory                          Behaviour                            Psychiatric illness                     
     Cranial nerves examination          Pupils         fundus           K.F.ring
Saccades      pursuit      gaze palsy       mask like facies     blink rate    jaw jerk
Release reflexes       glabellar         palmomental                   snout 
Spino motor system
Bulk        tone(cog wheel,leadpipe,axial rigidity)            posture             power
DTR          plantar         abd.reflex             cremastric                    Sensory         
 cerebellar                 autonomic(bladder,bowel,sweating,erectile dysfunction)
Gait           walk with support             walk without support       armswing 
UPDRS   scoring             Hoehn &yahr staging
(for all idiopathic parkinson’s disease cases)
Olfactory function tests
1)Odour identification test score -       Mild               Moderate             Severe
2)Odour discrimination test            Normal            Impaired 
3)Odour threshold test  Normal Elevated 
Investigations
 TC       DC       ESR        HB      Urea     Sugar    Creatinine         Lipid profile
Xray PNS(to ruleout sinusitis)                                                       CT Brain            
 MRI Brain(in cases of  PSP,MSA,Young onset parkinsonism)
Treatment History               
Drugs                  Duration of treatment                   Response to treatment
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